title: Pegylated liposomes have potential as vehicles for intratumoral and subcutaneous drug delivery.
abstract: The potential value of intratumoral or s.c. injections of pegylated liposomes as locoregionally targeted therapy of tumors and their draining lymph nodes was assessed in nude mice as part of an ongoing program aimed at developing pegylated liposomal radiosensitizers for the treatment of head and neck cancers. Animals received (111)In-labeled diethylenetriaminepentaacetic acid (DTPA), either encapsulated in pegylated liposomes (IDLPL) or in the unencapsulated form ((111)In-DTPA), as intratumoral or s.c. injections, and the local retention, locoregional nodal drainage, and systemic biodistribution were measured. After intratumoral injections, IDLPL were effectively retained in the tumor with an area under the curve (AUC) between 1 and 96 h of 2,574.4% injected dose per gram hours (%ID/g x h). The corresponding value for (111)In-DTPA was 204.4%ID/g x h. Accumulation of IDLPL was seen in ipsilateral lymph nodes. The maximal ipsilateral:contralateral node ratios were 8:1 (2.2 versus 0.27%ID/g) for inguinal nodes at 24 h and 19:1 (2.5 versus 0.13%ID/g) for axillary nodes at 48 h. Unencapsulated (111)In-DTPA showed no evidence of accumulation in locoregional nodes. After s.c. injection, IDLPL were cleared slowly from the injection site with an AUC between 1 and 192 h of 24,051.1%ID/g x h. Unencapsulated (111)In-DTPA was cleared rapidly with an AUC between 1 and 192 h of 46.4%ID/g x h. Again, significant levels of IDLPL were detected in the ipsilateral locoregional nodes, with ipsilateral:contralateral ratios of 121:1 (57.9 versus 0.48%ID/g) at 24 h (inguinal nodes) and 17:1 (5.2 versus 0.3%ID/g) at 72 h (axillary nodes). There was no retention of unencapsulated (111)In-DTPA in the draining nodes. Locoregional administration of pegylated liposomal radiosensitizers may be a useful approach for targeted therapy of head and neck tumors and their nodal metastases.
authors.affiliation: Imperial Cancer Research Fund Oncology Unit, Imperial College of Science, Technology and Medicine, Hammersmith Hospital, London, United Kingdom. Harrington.Kevin@mayo.edu
authors.forename: K J
authors.initials: KJ
authors.lastname: Harrington
authors.forename: G
authors.initials: G
authors.lastname: Rowlinson-Busza
authors.forename: K N
authors.initials: KN
authors.lastname: Syrigos
authors.forename: P S
authors.initials: PS
authors.lastname: Uster
authors.forename: R G
authors.initials: RG
authors.lastname: Vile
authors.forename: J S
authors.initials: JS
authors.lastname: Stewart
mesh_terms: D000818:Animals; D019540:Area Under Curve; D002614:Chelating Agents / Q000008:administration & dosage; D004337:Drug Carriers; D016503:Drug Delivery Systems; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D007279:Injections, Subcutaneous; D008081:Liposomes / Q000737:chemistry* / Q000493:pharmacokinetics; D008198:Lymph Nodes / Q000378:metabolism; D051379:Mice; D008819:Mice, Nude; D004369:Pentetic Acid / Q000008:administration & dosage; D011092:Polyethylene Glycols / Q000737:chemistry*; D011838:Radiation-Sensitizing Agents / Q000008:administration & dosage; D013997:Time Factors; D014018:Tissue Distribution
chemical_list: D002614:Chelating Agents; D004337:Drug Carriers; D008081:Liposomes; D011838:Radiation-Sensitizing Agents; D011092:Polyethylene Glycols; D004369:Pentetic Acid